Table 3.
Efficacy of UST on patients with anti-TNF exposure and anti-TNF naïve.
| Variables | Anti-TNF Naïve 1 | Anti-TNF Exposure | p Value |
|---|---|---|---|
| Intestinal clinical remission, n/n (%) (n = 108) | 30/38 (78.9) | 41/70 (58.6) | 0.033 |
| Intestinal clinical response, n/n (%) (n = 108) | 30/38 (78.9) | 47/70 (67.1) | 0.195 |
| Fistula clinical remission, n/n (%) (n = 108) | 20/38 (52.6) | 24/70 (34.3) | 0.064 |
| Fistula clinical response, n/n (%) (n = 108) | 25/38 (65.8) | 42/70 (60.0) | 0.554 |
| Endoscopic remission, n/n (%) (n = 99) | 14/35 (40.0) | 17/64 (26.6) | 0.381 |
| Endoscopic response, n/n (%) (n = 99) | 20/35 (57.1) | 25/64 (39.1) | 0.260 |
| Radiological remission, n/n (%) (n = 67) | 14/25 (56.0) | 16/42 (38.1) | 0.154 |
1 Anti-TNF agents refers to infliximab or/and adalimumab.